JPS6330941B2 - - Google Patents
Info
- Publication number
- JPS6330941B2 JPS6330941B2 JP57036841A JP3684182A JPS6330941B2 JP S6330941 B2 JPS6330941 B2 JP S6330941B2 JP 57036841 A JP57036841 A JP 57036841A JP 3684182 A JP3684182 A JP 3684182A JP S6330941 B2 JPS6330941 B2 JP S6330941B2
- Authority
- JP
- Japan
- Prior art keywords
- acid amide
- ethylene
- weight
- vinyl chloride
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229920001577 copolymer Polymers 0.000 claims description 20
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 claims description 19
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 18
- 239000005977 Ethylene Substances 0.000 claims description 18
- 229920005989 resin Polymers 0.000 claims description 18
- 239000011347 resin Substances 0.000 claims description 18
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims description 16
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 16
- -1 acid amide compound Chemical class 0.000 claims description 15
- 229940117927 ethylene oxide Drugs 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 239000011342 resin composition Substances 0.000 claims description 9
- 239000000395 magnesium oxide Substances 0.000 claims description 7
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 7
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 7
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 claims description 6
- 239000000292 calcium oxide Substances 0.000 claims description 6
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims description 6
- 150000002430 hydrocarbons Chemical group 0.000 claims description 4
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- KRGNPJFAKZHQPS-UHFFFAOYSA-N chloroethene;ethene Chemical group C=C.ClC=C KRGNPJFAKZHQPS-UHFFFAOYSA-N 0.000 claims description 2
- 229920001038 ethylene copolymer Polymers 0.000 claims description 2
- 239000008280 blood Substances 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 19
- 239000000203 mixture Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- LYRFLYHAGKPMFH-UHFFFAOYSA-N octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(N)=O LYRFLYHAGKPMFH-UHFFFAOYSA-N 0.000 description 11
- 150000001408 amides Chemical class 0.000 description 10
- 230000002949 hemolytic effect Effects 0.000 description 10
- ORAWFNKFUWGRJG-UHFFFAOYSA-N Docosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCC(N)=O ORAWFNKFUWGRJG-UHFFFAOYSA-N 0.000 description 8
- MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 description 5
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 5
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000004014 plasticizer Substances 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 229920000578 graft copolymer Polymers 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- OOCSVLHOTKHEFZ-UHFFFAOYSA-N icosanamide Chemical compound CCCCCCCCCCCCCCCCCCCC(N)=O OOCSVLHOTKHEFZ-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- QEALYLRSRQDCRA-UHFFFAOYSA-N myristamide Chemical compound CCCCCCCCCCCCCC(N)=O QEALYLRSRQDCRA-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 229940037312 stearamide Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- UKDKWYQGLUUPBF-UHFFFAOYSA-N 1-ethenoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOC=C UKDKWYQGLUUPBF-UHFFFAOYSA-N 0.000 description 1
- OEPOKWHJYJXUGD-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)-1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 OEPOKWHJYJXUGD-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 239000004709 Chlorinated polyethylene Substances 0.000 description 1
- 229920003314 Elvaloy® Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- RSSGSPAYFRXVKG-UHFFFAOYSA-N Tridecanamide Chemical compound CCCCCCCCCCCCC(N)=O RSSGSPAYFRXVKG-UHFFFAOYSA-N 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical class C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- AGXUVMPSUKZYDT-UHFFFAOYSA-L barium(2+);octadecanoate Chemical compound [Ba+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O AGXUVMPSUKZYDT-UHFFFAOYSA-L 0.000 description 1
- INLLPKCGLOXCIV-UHFFFAOYSA-N bromoethene Chemical compound BrC=C INLLPKCGLOXCIV-UHFFFAOYSA-N 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- TUTWLYPCGCUWQI-UHFFFAOYSA-N decanamide Chemical compound CCCCCCCCCC(N)=O TUTWLYPCGCUWQI-UHFFFAOYSA-N 0.000 description 1
- ILRSCQWREDREME-UHFFFAOYSA-N dodecanamide Chemical compound CCCCCCCCCCCC(N)=O ILRSCQWREDREME-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- AFSIMBWBBOJPJG-UHFFFAOYSA-N ethenyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC=C AFSIMBWBBOJPJG-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- XUCNUKMRBVNAPB-UHFFFAOYSA-N fluoroethene Chemical compound FC=C XUCNUKMRBVNAPB-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- LUOABWGXXKLFGZ-UHFFFAOYSA-N hexacosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(N)=O LUOABWGXXKLFGZ-UHFFFAOYSA-N 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- GHLZUHZBBNDWHW-UHFFFAOYSA-N nonanamide Chemical compound CCCCCCCCC(N)=O GHLZUHZBBNDWHW-UHFFFAOYSA-N 0.000 description 1
- LTHCSWBWNVGEFE-UHFFFAOYSA-N octanamide Chemical compound CCCCCCCC(N)=O LTHCSWBWNVGEFE-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229920006027 ternary co-polymer Polymers 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- ZAYKUYSGARCXKQ-UHFFFAOYSA-N tetracosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(N)=O ZAYKUYSGARCXKQ-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- FKVMWDZRDMCIAJ-UHFFFAOYSA-N undecanamide Chemical compound CCCCCCCCCCC(N)=O FKVMWDZRDMCIAJ-UHFFFAOYSA-N 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Description
【発明の詳細な説明】
本発明は医療器材、特に輪液保存用バツグ、血
液保存容器、人工腎臓の血液回路用チユーブ等を
構成するに適した樹脂組成物に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a resin composition suitable for constructing medical equipment, particularly a bag for storing ring fluid, a blood storage container, a tube for a blood circuit of an artificial kidney, and the like.
従来、医療用器材として例えば血液を運搬した
り保存するために血液バツグが使用され、又腎臓
障害の患者に対し人工腎臓による透析を行なうに
際し、血液回路用チユーブが使用される。そして
これらに要求される性質は柔軟であつて変質せ
ず、血液と永く接触しても血液を変質させたり、
血液中に異物を移行させたりするものであつては
ならない。 BACKGROUND ART Conventionally, blood bags have been used as medical equipment, for example, to transport and store blood, and blood circuit tubes have been used when performing dialysis using an artificial kidney for patients with renal failure. The properties required for these are to be flexible and not change in quality, and even if they come into contact with blood for a long time, they will not change the quality of the blood.
It must not transfer foreign substances into the blood.
又、血液回路用チユーブは、内部を通過する血
液を外側から観察できる透明性と、自在に変形し
うる柔軟性、チユーブの外側からクランプで締付
けたり外したりする際にチユーブが速やかに元の
形状に回復し、この操作によつて血流を随時止め
たりすることができる反揆弾性、チユーブ同志
が、癒着したりすることがない表面の非粘着性等
が要求される。 In addition, blood circuit tubes are transparent so that the blood passing through them can be observed from the outside, and flexible enough to be deformed freely, allowing the tube to quickly return to its original shape when clamped or removed from the outside of the tube. Resilient elasticity that allows the tubes to recover and stop blood flow at any time through this operation, and non-adhesive surfaces that prevent the tubes from adhering to each other are required.
ところで従来血液バツグや血液回路用チユーブ
は塩化ビニル系樹脂にジオクチルフタレートを多
量に添加して作られた組成物が使用されてきた。
この組成物は、柔軟性、透明性の点ではすぐれて
いるが、ジオクチルフタレートが僅かながら溶出
し、血液を通じて体内へ吸収、蓄積されることが
欠点とされた。また、血液回路用チユーブは、滅
菌のためにエチレンオキサイドガスをこれに接触
させることがあるが、このようなとき、エチレン
オキサイドを吸収する性質があることも欠点とさ
れた。 Conventionally, blood bags and tubes for blood circuits have been made from a composition made by adding a large amount of dioctyl phthalate to a vinyl chloride resin.
Although this composition has excellent flexibility and transparency, the disadvantage is that dioctyl phthalate is slightly eluted, absorbed into the body through the blood, and accumulated. In addition, blood circuit tubes are sometimes brought into contact with ethylene oxide gas for sterilization, but in such cases, their tendency to absorb ethylene oxide has also been considered a drawback.
そこでこのような欠点のない血液バツグ、血液
回賂用チユーブ構成用の樹脂組成物を作る必要が
あつた。 Therefore, there was a need to create a resin composition for constructing blood bags and blood circulation tubes that does not have these drawbacks.
本発明者等は上述のジオクチルフタレート含有
の塩化ビニル系樹脂が、若干の欠点を持ちながら
既に実際に使用され、日本薬局方や厚生省告示に
定められた試験基準に合格していることに着目
し、塩化ビニル系樹脂の改良を行ないジオクチル
フタレートを使用しない樹脂組成物により上記欠
点を解消しようとした。 The present inventors focused on the fact that the above-mentioned vinyl chloride resin containing dioctyl phthalate is already in use, although it has some drawbacks, and has passed the test standards set forth in the Japanese Pharmacopoeia and the Ministry of Health and Welfare notification. attempted to overcome the above drawbacks by improving vinyl chloride resins and creating resin compositions that do not use dioctyl phthalate.
そして可塑剤を実質的に使用することなく、塩
化ビニル系樹脂を軟質化する方法としてエチレ
ン・一酸化炭素・酢酸ビニルの三元共重合体が有
効であることを見出した。 They have also discovered that a ternary copolymer of ethylene, carbon monoxide, and vinyl acetate is effective as a method for softening vinyl chloride resin without substantially using a plasticizer.
しかしながらエチレン・一酸化炭素・酢酸ビニ
ルの三元共重合体に起因して表面粘着性を生ずる
ものとなつたので、更に鋭意検討を重ねた結果、
特定の酸アマイド系化合物を含有させることによ
つて表面粘着性を低くできることを見出し、本発
明を完成するに至つた。 However, due to the terpolymer of ethylene, carbon monoxide, and vinyl acetate, the surface became sticky, so after further investigation, we found that
The present inventors have discovered that surface tackiness can be lowered by incorporating a specific acid amide compound, and have completed the present invention.
本発明の要旨は、(イ)塩化ビニル系樹脂と、(ロ)エ
チレン・一酸化炭素・酢酸ビニル共重合体と、
(ハ)一般式
（但し、式中Ｒは炭素数が５上29以下である飽和
炭化水素基）で表わされる酸アマイド系化合物
と、酸化カルシウム微粉末又は（及び）酸化マグ
ネシウム微粉末とを含有する医療器材用樹脂組成
物に存する。次に本発明医療器材用樹脂組成物に
ついて更に詳細に説明する。 The gist of the present invention is (a) a vinyl chloride resin, (b) an ethylene/carbon monoxide/vinyl acetate copolymer, and (c) a general formula (However, in the formula, R is a saturated hydrocarbon group having 5 to 29 carbon atoms) and a resin for medical equipment containing an acid amide compound represented by the formula: calcium oxide fine powder or (and) magnesium oxide fine powder present in the composition. Next, the resin composition for medical equipment of the present invention will be explained in more detail.
本発明で用いられる塩化ビニル系樹脂は、塩化
ビニルの単独重合体に限らず、塩化ビニルの共重
合体であつてもよい。塩化ビニルの共重合体とし
ては、塩化ビニルと他の単量体とを共重合させて
得た共重合体のほか、他の重合体又は共重合体
に、塩化ビニルをグラフト重合させて得たグラフ
ト重合体をも用いることができる。 The vinyl chloride resin used in the present invention is not limited to a vinyl chloride homopolymer, but may be a vinyl chloride copolymer. Examples of vinyl chloride copolymers include copolymers obtained by copolymerizing vinyl chloride and other monomers, as well as copolymers obtained by graft polymerizing vinyl chloride onto other polymers or copolymers. Graft polymers can also be used.
上述の他の単量体としては、エチレン、プロピ
レン等のα―オレフイン類、酢酸ビニル、ステア
リン酸ビニル等のビニルエステル類、メチルビニ
ルエーテル、セチルビニルエーテル等のビニルエ
ーテル類、臭化ビニル、弗化ビニル等のハロゲン
化ビニル類、マレイン酸、無水マレイン酸、フマ
ル酸、等の不飽和酸類、及びこれらのエステル
類、スチレン、アクリロニトリル、塩化ビニリデ
ン等を挙げることができる。グラフト共重合体の
幹となる重合体又は共重合体としては、塩素化ポ
リエチレン、エチレン―酢酸ビニル共重合体、エ
チレン―プロピレン共重合体を挙げることができ
る。さらに、塩化ビニル樹脂を後塩素化して得
た。塩素化塩化ビニル樹脂も使用できる。 Other monomers mentioned above include α-olefins such as ethylene and propylene, vinyl esters such as vinyl acetate and vinyl stearate, vinyl ethers such as methyl vinyl ether and cetyl vinyl ether, vinyl bromide, vinyl fluoride, etc. Examples include vinyl halides, unsaturated acids such as maleic acid, maleic anhydride, and fumaric acid, and esters thereof, styrene, acrylonitrile, vinylidene chloride, and the like. Examples of the main polymer or copolymer of the graft copolymer include chlorinated polyethylene, ethylene-vinyl acetate copolymer, and ethylene-propylene copolymer. Furthermore, a vinyl chloride resin was obtained by post-chlorination. Chlorinated vinyl chloride resins can also be used.
本発明で用いられるエチレン・一酸化炭素・酢
酸ビニル共重合体は、例えばデユポン社製「エル
バロイ741」等が市販されているが、これらを含
めて１重量部のエチレンに対し0.03乃至0.5重量
部の一酸化炭素と0.1乃至0.9重量部の酢酸ビニル
を共重合させたものである。エチレン・一酸化炭
素・酢酸ビニル共重合体は塩化ビニル系樹脂100
重量部に対し５乃至200重量部の割合で使用する
のが好適であり、医療器材用樹脂組成物として優
れた柔軟性と透明性が得られる。 The ethylene/carbon monoxide/vinyl acetate copolymer used in the present invention is commercially available, for example, "Elvaloy 741" manufactured by DuPont, but including these, 0.03 to 0.5 parts by weight per 1 part by weight of ethylene. It is a copolymer of carbon monoxide and 0.1 to 0.9 parts by weight of vinyl acetate. Ethylene/carbon monoxide/vinyl acetate copolymer is vinyl chloride resin 100%
It is suitable to use it in a ratio of 5 to 200 parts by weight, and excellent flexibility and transparency can be obtained as a resin composition for medical equipment.
しかしながら塩化ビニル系樹脂とエチレン・一
酸化炭素・酢酸ビニル共重合体からなる組成物で
は、かゝる組成物より得られる医療器材を長時間
積重ねて放置するに際し相互間で癒着しやすく、
いわゆる表面粘着性を示しやすいので、特定の酸
アマイド化合物を含有させることによつて表面粘
着性を低下させるものである。 However, compositions made of vinyl chloride resins and ethylene/carbon monoxide/vinyl acetate copolymers tend to adhere to each other when medical devices obtained from such compositions are stacked and left for long periods of time.
Since it tends to exhibit so-called surface tackiness, the surface tackiness is reduced by containing a specific acid amide compound.
本発明において使用される酸アマイド系化合物
としては
一般式
（但し、式中Ｒは５以上29以下の飽和炭化水素
基）で表わされるものである。 The acid amide compound used in the present invention has the general formula (However, in the formula, R is a saturated hydrocarbon group of 5 or more and 29 or less).
かゝる酸アマイド系化合物としては、カプロン
酸アミド、カプリル酸アミド、ペラルゴニン酸ア
ミド、カプリン酸アミド、ウンデシリン酸アミ
ド、ラウリン酸アミド、トリデシリン酸アミド、
ミリスチン酸アミド、ペンタデシリン酸アミド、
バルミチン酸アミド、マーガリン酸アミド、ステ
アリン酸アミド、ノンデシリン酸アミド、アラキ
ジン酸アミド、ベヘニン酸アミド、リグノセリン
酸アミド、セロチン酸アミド等が挙げられる。 Such acid amide compounds include caproic acid amide, caprylic acid amide, pelargonic acid amide, capric acid amide, undecylic acid amide, lauric acid amide, tridecylic acid amide,
myristic acid amide, pentadecylinic acid amide,
Examples include valmitic acid amide, margaric acid amide, stearic acid amide, nondecylic acid amide, arachidic acid amide, behenic acid amide, lignoceric acid amide, cerotic acid amide, and the like.
上記の化合物の中で、特に好適なものは、融点
が100℃乃至115℃の範囲内にあり、分子量が200
乃至350の範囲内にあるものであり、例えばミリ
スチン酸アミド、バルミチン酸アミド、ステアリ
ン酸アミド、アラキジン酸アミド、ベヘニン酸ア
ミド等である。更に最適なものは、バルミチン酸
アミド及びステアリン酸アミドである。 Among the above compounds, particularly preferred ones have a melting point in the range of 100°C to 115°C and a molecular weight of 200°C.
Examples thereof include myristic acid amide, valmitic acid amide, stearic acid amide, arachidic acid amide, behenic acid amide, and the like. Further suitable are valmitic acid amide and stearic acid amide.
前記酸アマイド系化合物は前記した塩化ビニル
系樹脂とエチレン・一酸化炭素・酢酸ビニル共重
合体からなる組成物100重量部に対して0.05ない
し５重量部の比率で加えて使用されるのが好適で
ある。 The acid amide compound is preferably used in an amount of 0.05 to 5 parts by weight based on 100 parts by weight of the composition comprising the vinyl chloride resin and ethylene/carbon monoxide/vinyl acetate copolymer. It is.
そして前記酸アマイド系化合物は、エチレン・
一酸化炭素・酢酸ビニル共重合体に対し有効に作
用して表面粘着性を抑制させる。 The acid amide compound is ethylene/
Effectively acts on carbon monoxide/vinyl acetate copolymer to suppress surface tackiness.
この表面粘着性の抑制効果は、不飽和炭化水素
基を有する酸アマイド系化合物を使用する際には
殆んどもたらされることがなく、前記の飽和炭化
水素基を有する酸アマイド系化合物を使用した場
合において得られるものである。 This effect of suppressing surface tackiness is hardly achieved when an acid amide compound having an unsaturated hydrocarbon group is used; This is what can be obtained in certain cases.
本発明塩化ビニル系樹脂と、エチレン・一酸化
炭素・酢酸ビニル共重合体からなる樹脂混合物
と、前記酸アマイド系化合物を含有せしめて得ら
れる組成物は、溶血性や細胞毒性が僅少であり、
医療器材構成用組成物として好ましい性質を持つ
ものであるが、該組成物に酸化マグネシウム微粉
末又は（及び）酸化カルシウム微粉末を加えるこ
とによつて、上記溶血性及び細胞毒性が完全に抑
止される。酸化マグネシウム微粉末、酸化カルシ
ウム微粉末は何れも50μ以下の粒径を有するもの
であることが望ましい。 The composition obtained by containing the vinyl chloride resin of the present invention, a resin mixture consisting of an ethylene/carbon monoxide/vinyl acetate copolymer, and the acid amide compound has minimal hemolytic property and cytotoxicity;
Although it has favorable properties as a composition for medical device construction, by adding fine magnesium oxide powder or/and fine calcium oxide powder to the composition, the above-mentioned hemolytic properties and cytotoxicity can be completely suppressed. Ru. It is desirable that both the magnesium oxide fine powder and the calcium oxide fine powder have a particle size of 50 μm or less.
酸化マグネシウム微粉末、酸化カルシウム微粉
末は、該塩化ビニル系樹脂及びエチレン・一酸化
炭素・酢酸ビニル共重合体、前記酸アマイド系化
合物物からなる組成物100重量部に対し、0.01な
いし５重量部の範囲の比率で加えられることが望
ましい。 Magnesium oxide fine powder and calcium oxide fine powder are used in an amount of 0.01 to 5 parts by weight based on 100 parts by weight of the composition consisting of the vinyl chloride resin, ethylene/carbon monoxide/vinyl acetate copolymer, and the acid amide compound. It is desirable to add it at a ratio within the range of .
本発明おける組成物の熱安定性、耐老化性を改
善するために、血液等に有害な影響を及ぼさない
範囲内で、安定剤や可塑剤を該組成物中に配合す
ることができる。 In order to improve the thermal stability and aging resistance of the composition of the present invention, stabilizers and plasticizers can be incorporated into the composition within a range that does not have a harmful effect on blood or the like.
安定剤としては例えば、ステアリン酸カルシウ
ム、ステアリン酸亜鉛、ステアリン酸バリウム等
であり、可塑剤としてはエポキシ化大豆油、ジオ
クチルフタレート等を用いることができる。本発
明医療器材用樹脂組成物は上記した様に塩化ビニ
ル系樹脂と、エチレン・一酸化炭素・酢酸ビニル
共重合体と、前記酸アマイド系化合物と、酸化カ
ルシウム微粉末又は酸化マグネシウム微粉末とを
含有するものであるから、これにより得られる医
療器材は柔軟性、透明性に優れ且つ、溶血性、細
胞毒性を示さないのみならず、エチレン・一酸化
炭素・酢酸ビニル共重合体に起因する表面粘着性
が顕著に抑制され、医療器材を長時間積重ねて放
置するさいに、器材相互間で癒着したりする問題
が生じないものとなる。 As the stabilizer, for example, calcium stearate, zinc stearate, barium stearate, etc. can be used, and as the plasticizer, epoxidized soybean oil, dioctyl phthalate, etc. can be used. As described above, the resin composition for medical equipment of the present invention contains a vinyl chloride resin, an ethylene/carbon monoxide/vinyl acetate copolymer, the acid amide compound, and a fine calcium oxide powder or a fine magnesium oxide powder. The resulting medical equipment has excellent flexibility and transparency, and not only does not exhibit hemolysis or cytotoxicity, but also has a surface that is caused by ethylene, carbon monoxide, and vinyl acetate copolymers. Adhesion is significantly suppressed, and when medical instruments are left stacked for a long period of time, there is no problem of the instruments adhering to each other.
本発明医療器材用樹脂組成物は医療用カテーテ
ル、輸血や輸液用のチユーブ、血液バツグ、輸液
バツグ、人工透析における血液回路用チユーブ等
の医療器材の成形加工に好適に用いることができ
る。 The resin composition for medical equipment of the present invention can be suitably used for molding medical equipment such as medical catheters, tubes for blood transfusions and infusions, blood bags, infusion bags, and tubes for blood circuits in artificial dialysis.
以下に本発明の実施例を挙げる。なお、溶血性
試験は日本薬局法「一般試験法」のなかの輸液用
のプラスチツク容器試験法に準拠して行なつた。 Examples of the present invention are listed below. The hemolysis test was conducted in accordance with the plastic container test method for infusions in the "General test methods" of the Japanese Pharmacopoeia Law.
実施例 １
ポリ塩化ビニル（重合度1050）100重量部、エ
チレン・一酸化炭素、酢酸ビニル共重合体（エチ
レンの共重合成分量65重量％、一酸化炭素の共重
合成分量10重量％）80重量部、バルミチン酸アミ
ド0.8重量部、酸化マグネシウム0.3重量部、Ca―
Zn系安定剤0.6重量部、エポキシ化大豆油５重量
部を２本ロールに掛けて140℃で混練してロール
シートを得た。次いでこれを温度150℃、圧力100
Kg／cm2の条件下に３分間プレス成形し、平面の平
滑な厚さ0.5mmシートを成形した。このシートに
ついて溶血性試験を行なつた結果、溶血作用を全
く示さなかつた。次いで表面粘着性試験を行なつ
た。表面粘着性試験は、上記のシートを幅２cm、
長さ13cmの長方形の試験片に裁断し、これを２枚
重ね合わせて試験片の一方の端部より６cmまでの
部分に均一に500ｇ／12cm2の荷重を加えた状態で
50℃で24時間放置し、ブロツキングさせた試料を
10cm／分の引張速度でＴ型剥離させ、最大剥離力
を求めることによつて行なつた。その結果、最大
剥離力は24ｇ／２cmであり、バルミチン酸アミド
0.8重量部を使用しない場合の最大剥離力430ｇ／
２cmに比して小さく、表面粘着性が顕著に低減し
ていることが認められた。Example 1 100 parts by weight of polyvinyl chloride (degree of polymerization 1050), ethylene/carbon monoxide, vinyl acetate copolymer (copolymerized amount of ethylene 65% by weight, copolymerized amount of carbon monoxide 10% by weight) 80 Parts by weight, Valmitic acid amide 0.8 parts by weight, Magnesium oxide 0.3 parts by weight, Ca-
0.6 parts by weight of Zn-based stabilizer and 5 parts by weight of epoxidized soybean oil were placed on two rolls and kneaded at 140°C to obtain a rolled sheet. Next, this is heated to a temperature of 150℃ and a pressure of 100℃.
Press molding was carried out for 3 minutes under conditions of Kg/cm 2 to form a flat, smooth sheet with a thickness of 0.5 mm. A hemolytic test was conducted on this sheet, and it showed no hemolytic effect at all. A surface tack test was then conducted. The surface adhesion test was conducted using the above sheet with a width of 2 cm.
A rectangular test piece with a length of 13 cm was cut, two of these were stacked on top of each other, and a load of 500 g/12 cm 2 was applied uniformly to the area up to 6 cm from one end of the test piece.
The blocked sample was left at 50℃ for 24 hours.
This was done by performing T-peeling at a tensile speed of 10 cm/min and determining the maximum peeling force. As a result, the maximum peeling force was 24g/2cm, and valmitic acid amide
Maximum peeling force when not using 0.8 parts by weight: 430g/
It was observed that the surface tackiness was significantly reduced compared to 2 cm.
実施例 ２〜３
実施例１において、バルミチン酸アミド0.8重
量部にかえて、ステアリン酸アミド0.5重量部
（実施例２）、ベヘニン酸アミド0.5重量部（実施
例３）を夫々使用した以外は実施例１と全く同様
にしてシートを成形し、次いで溶血性試験、表面
粘着性試験を行なつた。Examples 2 to 3 In Example 1, except that 0.5 parts by weight of stearic acid amide (Example 2) and 0.5 parts by weight of behenic acid amide (Example 3) were used instead of 0.8 parts by weight of balmitic acid amide. A sheet was formed in exactly the same manner as in Example 1, and then a hemolytic test and a surface tack test were conducted.
その結果、いずれも溶血性を全く示さなかつ
た。又、最大剥離力は19ｇ／２cm（実施例２）、
21ｇ／２cm（実施例３）であり、ステアリン酸ア
ミドやベヘニン酸アミドを使用しない場合の最大
剥離力430ｇ／２cmに比して小さく、表面粘着性
が顕著に低減していることが認められた。 As a result, none of them showed any hemolytic properties. In addition, the maximum peeling force is 19g/2cm (Example 2),
The maximum peeling force was 21g/2cm (Example 3), which was smaller than the maximum peeling force of 430g/2cm when stearamide or behenicamide was not used, and it was observed that the surface tackiness was significantly reduced. .
実施例 ４
実施例１においてポリ塩化ビニル（重合度
1050）100重量部にかえて、塩化ビニル―エチレ
ン共重合体（重合度800、エチレンの共重合成分
量４重量％）100重量部を使用した以外は実施例
１と全く同様にしてシートを成形し、次いで溶血
性試験、表面粘着性試験を行なつた。その結果、
溶血性を全く示さなかつた。又、最大剥離力は36
ｇ／２cmであり、バルミチン酸アミド0.8重量部
を使用しない場合の最大剥離力490ｇ／２cmに比
して小さく、表面粘着性が顕著に低減しているこ
とが認められた。Example 4 In Example 1, polyvinyl chloride (polymerization degree
A sheet was molded in the same manner as in Example 1, except that 100 parts by weight of vinyl chloride-ethylene copolymer (degree of polymerization 800, ethylene copolymerization content 4% by weight) was used instead of 1050) 100 parts by weight. Then, a hemolytic test and a surface adhesion test were conducted. the result,
It showed no hemolytic properties. Also, the maximum peeling force is 36
g/2 cm, which was smaller than the maximum peeling force of 490 g/2 cm when 0.8 parts by weight of balmitic acid amide was not used, and it was recognized that the surface tackiness was significantly reduced.
実施例 ５〜６
実施例４においてバルミチン酸アミド0.8重量
部にかえて、ステアリン酸アミド0.5重量部（実
施例５）、ベヘニン酸アミド0.5重量部（実施例
６）を夫々使用した以外は実施例４と全く同様に
してシートを成形し、次いで溶血性試験、表面粘
着性試験を行なつた。Examples 5 to 6 Examples except that 0.5 parts by weight of stearic acid amide (Example 5) and 0.5 parts by weight of behenic acid amide (Example 6) were used in place of 0.8 parts by weight of balmitic acid amide in Example 4. A sheet was molded in exactly the same manner as in 4, and then a hemolytic test and a surface tack test were conducted.
その結果、いずれも溶血性を全く示さなかつ
た。又、最大剥離力は22ｇ／２cm（実施例５）、
27ｇ／２cm（実施例６）であり、ステアリン酸ア
ミド、ベヘニン酸アミドを使用しない場合の最大
剥離力490ｇ／２cmに比して小さく、表面粘着性
が顕著に低減していることが認められた。 As a result, none of them showed any hemolytic properties. In addition, the maximum peeling force is 22g/2cm (Example 5),
The maximum peeling force was 27 g/2 cm (Example 6), which was smaller than the maximum peeling force of 490 g/2 cm when stearamide and behenic acid amide were not used, and it was observed that the surface tackiness was significantly reduced. .
Claims (1)
炭素・酢酸ビニル共重合体と、 (ハ)一般式 （但し、式中Ｒは炭素数が５以上29以下である飽
和炭化水素基） で表わされる酸アマイド系化合物と、酸化カルシ
ウム微粉末又は（及び）酸化マグネシウム微粉末
とを含有する、医療器材用樹脂組成物。 ２ 塩化ビニル系樹脂が、塩化ビニル―エチレン
共重合体であることを特徴とする特許請求の範囲
第１項記載の医療器材用樹脂組成物。[Claims] 1 (a) vinyl chloride resin, (b) ethylene/carbon monoxide/vinyl acetate copolymer, (c) general formula (However, in the formula, R is a saturated hydrocarbon group having 5 or more and 29 or less carbon atoms.) A medical device containing an acid amide compound represented by the formula and calcium oxide fine powder or (and) magnesium oxide fine powder. Resin composition. 2. The resin composition for medical equipment according to claim 1, wherein the vinyl chloride resin is a vinyl chloride-ethylene copolymer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57036841A JPS58154746A (en) | 1982-03-08 | 1982-03-08 | Resin composition for medical facilities |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57036841A JPS58154746A (en) | 1982-03-08 | 1982-03-08 | Resin composition for medical facilities |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58154746A JPS58154746A (en) | 1983-09-14 |
| JPS6330941B2 true JPS6330941B2 (en) | 1988-06-21 |
Family
ID=12480977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57036841A Granted JPS58154746A (en) | 1982-03-08 | 1982-03-08 | Resin composition for medical facilities |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58154746A (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6114260A (en) * | 1984-06-29 | 1986-01-22 | Mitsubishi Petrochem Co Ltd | Resin composition having improved moldability |
| JP4543552B2 (en) * | 1998-08-21 | 2010-09-15 | 住友化学株式会社 | Polyurethane composition |
-
1982
- 1982-03-08 JP JP57036841A patent/JPS58154746A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS58154746A (en) | 1983-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1207489A (en) | Resin composition suitable for use in medical devices | |
| JPS6330941B2 (en) | ||
| JPS5829338B2 (en) | Resin composition for medical equipment construction | |
| JPS6350019B2 (en) | ||
| JPS6041945B2 (en) | Resin composition for medical equipment | |
| JPS6351027B2 (en) | ||
| JPS6351028B2 (en) | ||
| JPS6350018B2 (en) | ||
| JP2516996B2 (en) | Vinyl chloride resin composition for infusion containers | |
| JPS6041944B2 (en) | Resin composition for medical equipment | |
| JPS5969079A (en) | Resin composition for medical device | |
| JPS6096623A (en) | Production of resin molding | |
| JPS59199749A (en) | Resin composition for medical hardware | |
| JPS5971355A (en) | Resin composition for medical appliance | |
| JPH02209150A (en) | Blood or transfusion treating member | |
| JPS62106768A (en) | Resin composition for medical material | |
| JPH0525895B2 (en) | ||
| JP2006342343A (en) | Elastomer composition | |
| JPS639543B2 (en) | ||
| JPS59225063A (en) | Resin composition for medical device | |
| JPS6351030B2 (en) | ||
| JPH03184556A (en) | Resin composition for medical hardware | |
| JP2894793B2 (en) | Platelet storage bag | |
| JPS6351029B2 (en) | ||
| JPS6351026B2 (en) |